Regeneron Pharmaceuticals Inc(REGN)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $503.25 – $821.11
- YTD
- -20.64%
- IV Rank (30D)
- 4.76
- Straddle Price
- $43.00
- P/C Vol Ratio
- 0.08
- Market Cap
- $64.2B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.44% (VRP-adj) |
| WACC | 9.26% |
| Volatility Risk Premium | +1.1pp (IV − HV30), ERP adj -9bps |
| Effective Tax Rate | 14.2% |
| Rev. Growth (YoY, DCF input) | -1.9% |
| DCF Horizon | 12 years explicit + fade |
| Free Cash Flow (TTM) | $4.1B |
| Return on Equity (TTM) | 14.1% |
| Book / Price | 47.6% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 86.3% |
| FCF Margin (TTM) | 27.6% |
| Debt / Equity | 0.06 |
| Quality Score | 4/6 — high quality (12y DCF) |
| Market-Implied Growth | +3.2% (reverse-DCF on current price) |
| SMA 50 | $695.60 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $631.42 |
| Bollinger Width / SMA20 | 2.8% (drives anchor stability) |
| Net Debt | $-1.0B |
| Market Cap | $66B |
| Horizon | Expected α | z Pred | Blended z | Rank % | Active? |
|---|---|---|---|---|---|
| 21d | -3.4% | -0.14 | -0.59 | 61.1% | — |
| 42d | -8.7% | -1.01 | -0.59 | 61.1% | — |
| 63d | -13.3% | -1.57 | -0.59 | 61.1% | — |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $445.22 | 17% | |
| DDM (Gordon) | $31.47 | 13% | |
| Peer P/E | $1015.99 | 5% | median 24.8× · 3 peers |
| Peer EV/EBITDA | $410.22 | 5% | median 10.4× · 3 peers |
| Peer P/B | $866.86 | 5% | median 3.0× · 3 peers |
| Peer P/S | $317.66 | 5% | median 2.3× · 3 peers |
| Market Anchor (SMA50) | $695.60 | 33% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $616.21 | 17% | 45 strikes · skew -0.13 |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $64.2B
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +0.45% | 23 |
| Feb | +0.77% | 23 |
| Mar | +2.55% | 23 |
| Apr | +0.62% | 23 |
| May | +1.81% | 23 |
| Jun | -1.41% | 23 |
| Jul | +6.88% | 22 |
| Aug | +2.70% | 22 |
| Sep | -0.12% | 23 |
| Oct | +0.10% | 23 |
| Nov | +4.00% | 23 |
| Dec | +4.39% | 23 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-01 | Pre-Market | 4.83% | 1.29% | 0.27x | Within |
| 2024-10-31 | After-Close | 2.21% | 0.52% | 0.24x | Within |
| 2025-01-13 | After-Close | 4.74% | 3.25% | 0.69x | Within |
| 2025-04-29 | Pre-Market | 6.20% | 6.54% | 1.05x | Exceeded |
| 2025-08-01 | Pre-Market | 5.57% | 1.98% | 0.36x | Within |
| 2025-10-28 | Pre-Market | 5.41% | 11.76% | 2.17x | Exceeded |
| 2026-01-30 | Pre-Market | 5.67% | 1.32% | 0.23x | Within |
| 2026-04-29 | Pre-Market | 7.11% | 6.21% | 0.87x | Within |
- IV Rank (30D)
- 4.76
- IV Rank (7D)
- 24.41
- Avg IV
- 49.1%
- Straddle (30D)
- $43.00
- Straddle (7D)
- $21.05
- P/C Volume
- 0.08
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.50
- Correlation (SPY)
- 18.8%
- R²
- 0.04
- Ann. Volatility
- 32.8%
- SPY Volatility
- 12.3%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $259.38M | 24.14% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $165.11M | 15.37% | 2026-03-31 |
| 3 | GOLDMAN SACHS GROUP INC Custodian | $144.95M | 13.49% | 2026-03-31 |
| 4 | JANE STREET GROUP, LLC Custodian | $124.78M | 11.61% | 2026-03-31 |
| 5 | IMC-Chicago, LLC Custodian | $110.18M | 10.26% | 2026-03-31 |
| 6 | Bronte Capital Management Pty Ltd. | $52.95M | 4.93% | 2026-03-31 |
| 7 | WOLVERINE TRADING, LLC Custodian | $45.93M | 4.27% | 2025-09-30 |
| 8 | Nantahala Capital Management, LLC | $30.91M | 2.88% | 2026-03-31 |
| 9 | MILLENNIUM MANAGEMENT LLC Custodian | $21.79M | 2.03% | 2026-03-31 |
| 10 | ROYAL BANK OF CANADA Custodian | $13.60M | 1.27% | 2026-03-31 |
| 11 | SIMPLEX TRADING, LLC Custodian | $12.75M | 1.19% | 2026-03-31 |
| 12 | GROUP ONE TRADING LLC Custodian | $11.67M | 1.09% | 2026-03-31 |
| 13 | SIG BROKERAGE, LP | $11.59M | 1.08% | 2026-03-31 |
| 14 | Squarepoint Ops LLC | $8.42M | 0.78% | 2026-03-31 |
| 15 | JPMORGAN CHASE & CO Custodian | $7.49M | 0.70% | 2026-03-31 |
| 16 | UBS Group AG Custodian | $7.26M | 0.68% | 2026-03-31 |
| 17 | Qube Research & Technologies Ltd | $6.49M | 0.60% | 2026-03-31 |
| 18 | Cubist Systematic Strategies, LLC | $4.84M | 0.45% | 2025-09-30 |
| 19 | PEAK6 LLC | $4.71M | 0.44% | 2026-03-31 |
| 20 | Alphadyne Asset Management LP | $4.56M | 0.42% | 2026-03-31 |
| 21 | Walleye Trading LLC | $3.79M | 0.35% | 2026-03-31 |
| 22 | BNP PARIBAS FINANCIAL MARKETS Custodian | $3.63M | 0.34% | 2026-03-31 |
| 23 | Point72 Asset Management, L.P. | $3.55M | 0.33% | 2026-03-31 |
| 24 | Allianz Asset Management GmbH | $3.01M | 0.28% | 2026-03-31 |
| 25 | NOMURA HOLDINGS INC | $1.55M | 0.14% | 2026-03-31 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $469.61M | 40.78% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $133.20M | 11.57% | 2026-03-31 |
| 3 | Point72 Asset Management, L.P. | $111.11M | 9.65% | 2026-03-31 |
| 4 | JANE STREET GROUP, LLC Custodian | $87.85M | 7.63% | 2026-03-31 |
| 5 | IMC-Chicago, LLC Custodian | $76.18M | 6.62% | 2026-03-31 |
| 6 | GROUP ONE TRADING LLC Custodian | $37.32M | 3.24% | 2026-03-31 |
| 7 | WOLVERINE TRADING, LLC Custodian | $36.50M | 3.17% | 2025-09-30 |
| 8 | MILLENNIUM MANAGEMENT LLC Custodian | $31.91M | 2.77% | 2026-03-31 |
| 9 | LMR Partners LLP | $30.13M | 2.62% | 2026-03-31 |
| 10 | SIMPLEX TRADING, LLC Custodian | $16.61M | 1.44% | 2026-03-31 |
| 11 | Eisler Capital Management Ltd. | $16.08M | 1.40% | 2025-09-30 |
| 12 | GOLDMAN SACHS GROUP INC Custodian | $12.75M | 1.11% | 2026-03-31 |
| 13 | JPMORGAN CHASE & CO Custodian | $11.24M | 0.98% | 2026-03-31 |
| 14 | HSBC HOLDINGS PLC Custodian | $10.01M | 0.87% | 2026-03-31 |
| 15 | UBS Group AG Custodian | $9.74M | 0.85% | 2026-03-31 |
| 16 | Squarepoint Ops LLC | $7.11M | 0.62% | 2026-03-31 |
| 17 | D. E. Shaw & Co., Inc. Custodian | $6.03M | 0.52% | 2026-03-31 |
| 18 | Alphadyne Asset Management LP | $5.64M | 0.49% | 2026-03-31 |
| 19 | Qube Research & Technologies Ltd | $5.41M | 0.47% | 2026-03-31 |
| 20 | Allianz Asset Management GmbH | $5.18M | 0.45% | 2026-03-31 |
| 21 | Verition Fund Management LLC | $5.18M | 0.45% | 2026-03-31 |
| 22 | Walleye Trading LLC | $4.48M | 0.39% | 2026-03-31 |
| 23 | CAPSTONE INVESTMENT ADVISORS, LLC | $3.32M | 0.29% | 2026-03-31 |
| 24 | BNP PARIBAS FINANCIAL MARKETS Custodian | $3.09M | 0.27% | 2026-03-31 |
| 25 | J. Goldman & Co LP | $3.09M | 0.27% | 2026-03-31 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-04 | ARTHUR F RYAN | Director | Sell (S) | −100 | $705.24 | -$70.5K | EDGAR |
| 2026-04-03 | ARTHUR F RYAN | Director | Sell (S) | −100 | $777.27 | -$77.7K | EDGAR |
| 2026-03-03 | ARTHUR F RYAN | Director | Sell (S) | −100 | $785.50 | -$78.5K | EDGAR |
| 2026-02-23 | Huda Y Zoghbi | Director | Mixed | — | $579.01 | -$662.8K | EDGAR |
| 2026-02-11 | ARTHUR F RYAN | Director | Sell (S) | −100 | $778.53 | -$77.9K | EDGAR |
| 2026-02-11 | Jason Pitofsky | SVP Controller | Mixed | −1,036 | $684.14 | -$1.09M | EDGAR |
| 2026-01-08 | Bonnie L Bassler | Director | Mixed | — | $587.06 | -$638.8K | EDGAR |
| 2026-01-06 | CHRISTINE A POON | Director | Award (A) | +155 | — | EDGAR | |
| 2026-01-06 | Bonnie L Bassler | Director | Award (A) | +155 | — | EDGAR | |
| 2026-01-06 | MICHAEL S BROWN | Director | Award (A) | +155 | — | EDGAR | |
| 2026-01-06 | N ANTHONY COLES | Director | Award (A) | +155 | — | EDGAR | |
| 2026-01-06 | ARTHUR F RYAN | Director | Award (A) | +155 | — | EDGAR | |
| 2026-01-06 | JOSEPH L GOLDSTEIN | Director | Award (A) | +155 | — | EDGAR | |
| 2026-01-06 | David P Schenkein | Director | Award (A) | +155 | — | EDGAR | |
| 2026-01-06 | Kathryn Guarini | Director | Award (A) | +155 | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Amerique du Nord S.N.C. Sanofi-Aventis | 10%+ Owner | 15,816,953 | $9.68B | $56.97M | 1 | 2010-10-14 |
| 2 | GEORGE YANCOPOULOS | Bd. Co-Chair, President & CSO | 510,460 | $312.47M | -$467.64M | 57 | 2026-01-05 |
| 3 | LEONARD S SCHLEIFER | Bd. Co-Chair, President & CEO | 370,577 | $226.85M | -$458.80M | 50 | 2026-01-05 |
| 4 | P ROY VAGELOS | Director | 336,039 | $205.70M | -$379.01M | 75 | 2023-04-05 |
| 5 | Sanofi | 10%+ Owner | 279,766 | $171.26M | -$9.52B | 46 | 2020-06-11 |
| 6 | MURRAY A GOLDBERG | SVP Administration & Asst Secr | 70,086 | $42.90M | -$56.70M | 46 | 2014-12-18 |
| 7 | NEIL STAHL | EVP Research and Development | 53,434 | $32.71M | -$151.48M | 66 | 2024-12-18 |
| 8 | ANDREW J MURPHY | EVP Research | 52,208 | $31.96M | -$57.65M | 29 | 2025-12-11 |
| 9 | Daniel P Van Plew | EVP & General Mgr, Industrial | 34,049 | $20.84M | -$135.29M | 55 | 2025-12-11 |
| 10 | GEORGE L SING | Director | 31,407 | $19.23M | -$146.52M | 60 | 2026-01-06 |
| 11 | JOSEPH J LAROSA | EVP General Counsel and Secret | 31,309 | $19.17M | -$42.93M | 45 | 2025-12-09 |
| 12 | Peter Powchik | SVP Clinical Development & Reg | 27,388 | $16.77M | -$40.97M | 26 | 2016-12-19 |
| 13 | Robert J Terifay | EVP Commercial | 26,913 | $16.47M | -$52.21M | 30 | 2017-12-13 |
| 14 | Robert E Landry | EVP Finance CFO | 23,963 | $14.67M | -$23.25M | 60 | 2024-02-06 |
| 15 | WILLIAM ROBERTS | VP Reg Dev & Med Safety | 21,844 | $13.37M | -$15.61M | 26 | 2013-09-20 |
| 16 | STUART KOLINSKI | SVP General Counsel and Secret | 20,039 | $12.27M | -$501.5K | 7 | 2010-06-07 |
| 17 | Michael S Aberman | SVP Strategy Investor Relation | 18,767 | $11.49M | -$16.86M | 25 | 2017-06-23 |
| 18 | Christopher R. Fenimore | EVP Finance CFO | 18,325 | $11.22M | -$30.33M | 38 | 2025-12-09 |
| 19 | ARTHUR F RYAN | Director | 17,503 | $10.71M | -$59.29M | 80 | 2026-05-04 |
| 20 | Marion McCourt | EVP Commercial | 14,546 | $8.90M | -$30.98M | 60 | 2025-12-11 |
| 21 | Douglas S McCorkle | VP Controller and Asst Treasur | 10,995 | $6.73M | -$28.03M | 33 | 2015-12-29 |
| 22 | ALFRED G GILMAN | Director | 10,612 | $6.50M | -$34.31M | 26 | 2015-08-07 |
| 23 | CHARLES A BAKER | Director | 9,000 | $5.51M | -$28.08M | 29 | 2018-01-03 |
| 24 | MICHAEL S BROWN | Director | 7,865 | $4.81M | -$73.07M | 81 | 2026-01-06 |
| 25 | ERIC M SHOOTER | Director | 7,000 | $4.28M | -$22.04M | 22 | 2014-02-13 |
| 26 | JOSEPH L GOLDSTEIN | Director | 6,703 | $4.10M | -$72.45M | 96 | 2026-01-06 |
| 27 | ROBERT ALEXANDER INGRAM | Director | 6,667 | $4.08M | -$708.0K | 2 | 2015-05-27 |
| 28 | CHRISTINE A POON | Director | 5,219 | $3.19M | -$70.40M | 25 | 2026-01-06 |
| 29 | Jason Pitofsky | SVP Controller | 4,712 | $2.88M | -$2.39M | 6 | 2026-02-11 |
| 30 | RANDALL RUPP | SVP, Manufuring Operations | 3,983 | $2.44M | -$781.1K | 1 | 2007-04-17 |
| 31 | Huda Y Zoghbi | Director | 3,341 | $2.05M | -$11.25M | 18 | 2026-02-23 |
| 32 | Marc Tessier-Lavigne | Director | 2,434 | $1.49M | -$54.63M | 25 | 2023-01-05 |
| 33 | N ANTHONY COLES | Director | 1,714 | $1.05M | -$20.62M | 16 | 2026-01-06 |
| 34 | Bonnie L Bassler | Director | 1,703 | $1.04M | -$22.33M | 33 | 2026-01-08 |
| 35 | Craig B. Thompson | Director | 775 | $474.4K | $0 | 5 | 2026-01-06 |
| 36 | David P Schenkein | Director | 603 | $369.1K | $0 | 4 | 2026-01-06 |
| 37 | Kathryn Guarini | Director | 603 | $369.1K | $0 | 4 | 2026-01-06 |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-29 | 0000872589-26-000014 | EDGAR |
| 2026-04-08 | 0001104659-26-040661 | EDGAR |
| 2026-01-30 | 0000872589-26-000004 | EDGAR |
| 2026-01-12 | 0001104659-26-002691 | EDGAR |
| 2025-10-28 | 0000872589-25-000026 | EDGAR |
| 2025-10-06 | 0001104659-25-096921 | EDGAR |
| 2025-08-01 | 0000872589-25-000017 | EDGAR |
| 2025-06-18 | 0001104659-25-060637 | EDGAR |
| 2025-04-29 | 0001804220-25-000020 | EDGAR |
| 2025-02-04 | 0001804220-25-000007 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-04 | 0000872589-26-000008 | EDGAR |
| 2025-02-05 | 0001804220-25-000011 | EDGAR |
| 2024-02-05 | 0001804220-24-000009 | EDGAR |
| 2023-02-06 | 0001804220-23-000008 | EDGAR |
| 2022-02-07 | 0001804220-22-000007 | EDGAR |
| 2021-02-08 | 0001804220-21-000008 | EDGAR |
| 2020-02-07 | 0001532176-20-000008 | EDGAR |
| 2019-02-07 | 0001532176-19-000009 | EDGAR |
| 2018-02-08 | 0001532176-18-000013 | EDGAR |
| 2017-02-09 | 0001532176-17-000008 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-29 | 0000872589-26-000016 | EDGAR |
| 2025-10-28 | 0000872589-25-000028 | EDGAR |
| 2025-08-01 | 0000872589-25-000019 | EDGAR |
| 2025-04-29 | 0001804220-25-000022 | EDGAR |
| 2024-10-31 | 0001804220-24-000040 | EDGAR |
| 2024-08-01 | 0001804220-24-000028 | EDGAR |
| 2024-05-02 | 0001804220-24-000017 | EDGAR |
| 2023-11-02 | 0001804220-23-000031 | EDGAR |
| 2023-08-03 | 0001804220-23-000023 | EDGAR |
| 2023-05-04 | 0001804220-23-000016 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/E Ratio | 15.0 |
| P/B Ratio | 2.0 |
| P/S Ratio | 4.3 |
| EV/EBITDA | 15.3 |
| TTM Revenue | $14.9B |
| TTM Net Income | $4.4B |
| TTM EPS | $41.05 |
| ROE | 14.1% |
| Dividend Yield | 0.58% |
| Debt/Equity | 0.09 |